Kohjin Bio Co., Ltd. (TYO:177A)

Japan · Delayed Price · Currency is JPY

963.00

+1.00 (0.10%)

Jun 24, 2026, 3:30 PM JST

-44.78% (1Y)

Market Cap	4.92B -41.2%
Revenue (ttm)	4.94B -5.1%
Net Income	251.00M -68.4%
EPS	49.10 -68.8%
Shares Out	5.11M
PE Ratio	19.61
Forward PE	n/a
Dividend	25.00 (2.60%)
Ex-Dividend Date	Mar 30, 2026

Volume	500
Open	977.00
Previous Close	962.00
Day's Range	963.00 - 977.00
52-Week Range	961.00 - 2,020.00
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Kohjin Bio

Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreserva... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1981

Employees 167

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 177A

Full Company Profile

Financial Performance

In fiscal year 2026, Kohjin Bio's revenue was 4.94 billion, a decrease of -5.13% compared to the previous year's 5.21 billion. Earnings were 251.00 million, a decrease of -68.39%.

Financial Statements